Press release
Diabetic Gastroparesis Pipeline: Emerging Therapies and Innovations in Gastrointestinal Management | DelveInsight
Diabetic Gastroparesis Pipeline
DelveInsight's "Diabetic Gastroparesis - Pipeline Insight, 2025" offers a thorough analysis of the ongoing clinical and preclinical development of investigational therapies. The report highlights promising drug candidates, biological treatments, and innovative approaches targeting the underlying pathophysiology of DG. Key therapeutic strategies include prokinetic agents, neurostimulation devices, targeted biologics, and gene therapies aimed at restoring gastric function and addressing the root causes of delayed gastric emptying.
This report provides detailed insights into therapies at all stages of development, examining administration routes, delivery mechanisms, and geographical trial trends. It also explores unmet clinical needs, emerging scientific innovations, regulatory milestones (e.g., breakthrough therapy designations, orphan drug status), and potential strategic partnerships that could redefine the treatment approach for Diabetic Gastroparesis in the near future.
Interested in learning more about the current treatment landscape and the key drivers shaping the diabetic gastroparesis pipeline? Click here: https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Diabetic Gastroparesis Pipeline Report
• DelveInsight's diabetic gastroparesis pipeline analysis depicts a strong space with 6+ active players working to develop 8+ pipeline drugs for diabetic gastroparesis treatment.
• The leading diabetic gastroparesis companies include Neurogastrx, Vanda Pharmaceuticals, Takeda, Processa Pharmaceuticals, Theravance Biopharma, and others are evaluating their lead assets to improve the diabetic gastroparesis treatment landscape.
• Key diabetic gastroparesis pipeline therapies in various stages of development include TD 1473, NG101, PCS-12852, THRX-149699, Camicinal, and others.
• In April 2025, Vanda Pharmaceuticals accused the FDA of deliberately delaying its request for a hearing on tradipitant's approvability for gastroparesis, blaming internal bureaucracy and recent leadership changes, including the appointment of Commissioner Dr. Martin Makary and agency staffing cuts.
• In January 2025, Vanda Pharmaceuticals accepted the FDA's hearing for the NDA of Tradipitant for gastroparesis, a digestive disorder with no new FDA-approved treatments in over 40 years. Current therapies are often ineffective, and studying new drugs is difficult due to symptom variability and placebo effects.
Request a sample and discover the recent breakthroughs happening in the diabetic gastroparesis pipeline landscape @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Diabetic Gastroparesis Overview
Diabetic Gastroparesis is a form of gastroparesis caused by diabetes. Its symptoms can vary in severity from person to person and may include nausea, vomiting, heartburn, loss of appetite, weight loss, bloating, unstable blood sugar levels, gastroesophageal reflux, and stomach spasms. This condition is more common in women and individuals who have undergone surgery around the esophagus, stomach, or small intestine, as such procedures can impact the vagus nerve. According to the American College of Gastroenterology (ACG) guidelines, the diagnosis of Diabetic Gastroparesis requires a combination of specific symptoms, signs, and delayed gastric emptying, without gastric outlet obstruction or ulceration. Treatment typically includes nutritional assessment, dietary changes, glycemic control, and the use of prokinetic and antiemetic medications.
Find out more about diabetic gastroparesis medication @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Diabetic Gastroparesis Treatment Analysis: Drug Profile
PCS-12852: Processa Pharmaceuticals
PCS-12852 is an innovative, highly selective 5-HT4 receptor agonist designed to treat gastrointestinal (GI) motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia, and gastroparesis. The drug is currently undergoing Phase II clinical trials for the treatment of Diabetic Gastroparesis.
NG101: Neurogastrx
NG101 is a potent and selective dopamine D2 receptor antagonist that is peripherally restricted. It is in Phase II clinical trials for treating Diabetic Gastroparesis. Preclinical studies from Neurogastrx have demonstrated that, in addition to its strong antiemetic effects, NG101 is also expected to significantly enhance gastric motility, making it a promising candidate for gastroparesis treatment.
Learn more about the novel and emerging diabetic gastroparesis pipeline therapies @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Diabetic Gastroparesis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Scope of the Diabetic Gastroparesis Pipeline Report
• Coverage: Global
• Key Diabetic Gastroparesis Companies: Neurogastrx, Vanda Pharmaceuticals, Takeda, Processa Pharmaceuticals, Theravance Biopharma, and others.
• Key Diabetic Gastroparesis Pipeline Therapies: TD 1473, NG101, PCS-12852, THRX-149699, Camicinal, and others.
Dive deep into rich insights for drugs used for diabetic gastroparesis treatment; visit @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Diabetic Gastroparesis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Diabetic Gastroparesis Pipeline Therapeutics
6. Diabetic Gastroparesis Pipeline: Late-Stage Products (Phase III)
7. Diabetic Gastroparesis Pipeline: Mid-Stage Products (Phase II)
8. Diabetic Gastroparesis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading market research and business consulting firm specializing in the life sciences industry. We provide pharmaceutical companies with tailored, end-to-end solutions to optimize their strategies and enhance business outcomes. With our subscription-based platform, PharmDelve, you can access a comprehensive range of healthcare and pharma market research reports, ensuring informed decision-making and sustained growth.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Gastroparesis Pipeline: Emerging Therapies and Innovations in Gastrointestinal Management | DelveInsight here
News-ID: 4014010 • Views: …
More Releases from DelveInsight
PH-ILD Market Size in the 7MM was ~USD 3 Billion in 2024 and is projected to inc …
DelveInsight's "Pulmonary Hypertension associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of PH-ILD, historical and forecasted epidemiology, as well as the PH-ILD market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover Key Insights into the Pulmonary Hypertension associated with Interstitial Lung Disease Market with DelveInsight's In-Depth Report @ Pulmonary Hypertension associated with…
Sensorineural Hearing Loss Clinical Trials Analysis 2025: Emerging Regenerative …
DelveInsight's "Sensorineural Hearing Loss Clinical Trials Analysis, 2025" describes a rapidly evolving pipeline targeting both restoration of inner-ear structures and symptomatic improvement. Ongoing programs span hair cell regeneration via small molecules and biologics, AAV- and non-viral gene-replacement or gene-editing strategies for monogenic deafness, cell-based therapies (supporting synaptic reconnection), and cochlear neuromodulation advancements to augment residual hearing. Trials increasingly pair novel delivery methods (e.g., intracochlear, round-window) with precision patient selection based…
Cell and Gene Therapy in Parkinson's Disease Clinical Trials Analysis 2025: Dise …
DelveInsight's "Cell and Gene Therapy in Parkinson's Disease - Clinical Trials Analysis, 2025" highlights a diversified development landscape pursuing symptomatic relief and disease modification. Programs include dopamine-restorative cell implants, neuroprotective gene therapies targeting α-synuclein aggregation or neuroinflammation, and circuit-targeted gene delivery to rebalance basal ganglia networks. Trials incorporate advanced delivery (stereotactic infusion), standardized imaging and molecular biomarkers, and combination strategies pairing cell/gene therapy with neuromodulation.
Pivotal and late-phase trials focus on…
Staphylococcal Infections Clinical Trials Analysis 2025: New Antibacterials, Ant …
DelveInsight's "Staphylococcal Infections Clinical Trials Analysis, 2025" outlines a focused effort to tackle antibiotic resistance and severe invasive disease. Active programs include novel small-molecule antibacterials with activity against MRSA, anti-virulence and quorum-sensing inhibitors, monoclonal antibodies targeting toxins and surface proteins, and host-directed immunotherapies to enhance clearance. Trials cover a range of indications from complicated skin and soft tissue infections to bacteremia and prosthetic-joint infections, with increasing attention on combination regimens…
More Releases for Diabetic
Rising Diabetic Population Fuels Growth In The Diabetic Footwear Market Emerges …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Diabetic Footwear Market Through 2025?
The size of the market for diabetic footwear has seen significant expansion in the past few years. From $8.45 billion in 2024, it is set to increase to $9.2 billion in 2025, exhibiting a compound annual growth…
Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring…
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report.
On the basis of…
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and…
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025.
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282
Global Diabetic Socks Market: Factors Impacting the Market
The primary factors driving the growth of the global diabetic socks market are increasing…
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be…
